loading
Schlusskurs vom Vortag:
$1.73
Offen:
$1.79
24-Stunden-Volumen:
130.94K
Relative Volume:
3.27
Marktkapitalisierung:
$11.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.5213
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+27.61%
1M Leistung:
+27.22%
6M Leistung:
-48.13%
1J Leistung:
-47.74%
1-Tages-Spanne:
Value
$1.73
$2.11
1-Wochen-Bereich:
Value
$1.63
$2.11
52-Wochen-Spanne:
Value
$1.412
$5.01

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name
Firmenname
Aprea Therapeutics Inc
Name
Telefon
215-948-4119
Name
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-07
Name
Neueste SEC-Einreichungen
Name
APRE's Discussions on Twitter

Vergleichen Sie APRE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
APRE
Aprea Therapeutics Inc
2.08 9.02M 0 -14.29M -12.27M -3.99
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-12-28 Herabstufung Robert W. Baird Outperform → Neutral
2020-12-16 Eingeleitet Berenberg Buy
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-06-22 Eingeleitet H.C. Wainwright Neutral
2020-04-21 Eingeleitet Robert W. Baird Outperform
2019-10-28 Eingeleitet JP Morgan Neutral
2019-10-28 Eingeleitet Morgan Stanley Equal-Weight
2019-10-28 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Aprea Therapeutics Inc. stockOverwhelming profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Aprea Therapeutics Inc. Stock Analysis and ForecastTriple-digit wealth increases - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Is Aprea Therapeutics Inc. a good long term investmentLightning-fast growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What drives Aprea Therapeutics Inc. stock priceUnmatched profit potential - Autocar Professional

Jul 21, 2025
pulisher
Jul 19, 2025

Franklin Covey Co. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

What analysts say about AMBO stockExplosive earning power - Jammu Links News

Jul 18, 2025
pulisher
Jul 16, 2025

Why Aprea Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Courses - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Aprea Therapeutics Inc. stock price move sharplyFree Access to Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Rocky Mountain Chocolate Factory Inc. stock performs during market volatilityFree Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Aprea Therapeutics Inc. stock performs during market volatilityConsistent High Return Strategy - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value - simplywall.st

Jul 10, 2025
pulisher
Jul 10, 2025

Aprea Therapeutics (NASDAQ:APRE) Trading 4.4% Higher – What’s Next? - Defense World

Jul 10, 2025
pulisher
Jun 30, 2025

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MSN

Jun 30, 2025
pulisher
Jun 27, 2025

Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers - MSN

Jun 27, 2025
pulisher
Jun 27, 2025

Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World

Jun 27, 2025
pulisher
Jun 25, 2025

Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center - Morningstar

Jun 25, 2025
pulisher
Jun 17, 2025

Chronic Lymphocytic Leukemia Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 12, 2025

CoreWeave Stock Skyrockets 137% In A Month: Hold Or Fold? - Barchart.com

Jun 12, 2025
pulisher
Jun 11, 2025

Block Inc. Has Unusual Put Option ActivityShowing Bullish XYZ Investors - Barchart.com

Jun 11, 2025
pulisher
Jun 11, 2025

Ostara Inc. Launches CG P2X In Western Canada: Phosphorus, Perfected - Barchart.com

Jun 11, 2025
pulisher
Jun 11, 2025

Stocks In Play: WSP Global Inc. - Barchart.com

Jun 11, 2025
pulisher
Jun 10, 2025

Alzheimer’s Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

Jun 10, 2025
pulisher
Jun 10, 2025

Polycystic Kidney Disease Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

Jun 10, 2025
pulisher
Jun 10, 2025

Dry Eye Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - Barchart.com

Jun 10, 2025
pulisher
Jun 10, 2025

Supporting 2SLGBTQI+ Communities For A Safer, More Equitable And Inclusive Canada - Barchart.com

Jun 10, 2025
pulisher
Jun 10, 2025

Artios' AACR Data Success: What It Means For Aprea Therapeutics' ATRN-119 Program - Barchart.com

Jun 10, 2025
pulisher
Jun 10, 2025

REKO INTERNATIONAL GROUP INC. TO BUY BACK UP TO 276,066 OF ITS COMMON SHARES - Barchart.com

Jun 10, 2025
pulisher
Jun 09, 2025

Aprea Therapeutics Confirms Directors and Accounting Firm - TipRanks

Jun 09, 2025
pulisher
Jun 06, 2025

Stocks Finish Sharply Higher On A Resilient US Labor Market - Barchart.com

Jun 06, 2025
pulisher
Jun 06, 2025

Compass Refresh, Inc. Launches New Headquarters in Sulphur Springs, TX – Bringing High-Quality Exterior Maintenance Across the Southern Region - Barchart.com

Jun 06, 2025
pulisher
Jun 05, 2025

Aprea Therapeutics expands cancer drug patent portfolio - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Stocks In Play: Aimia Inc. - Barchart.com

Jun 04, 2025
pulisher
Jun 04, 2025

ADF GROUP INC. Q1-2026 CONFERENCE CALL INVITATION - Barchart.com

Jun 04, 2025

Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):